Withdrawal
Managing Patients Taking Xylazine-Adulterated Opioids in Emergency, Hospital, and Addiction Care Settings
Guidelines for Managing Substance Withdrawal in Jails: A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals
TIP 42: Substance Use Treatment for Persons With Co-Occurring Disorders
Managing Substance Withdrawal in Jails: A Legal Brief
CDC Evaluates State-Led Surveillance of Neonatal Abstinence Syndrome
RCORP 2021 (Region 5 Meeting): Stimulants 2021, An Update—Clinical Issues and Treatments
RCORP 2021: Regions 6 and 7 Meeting - Morning Breakout Sessions (Day 2)
Session 1: Stimulants 2021: An Update—Clinical Issues and Treatments: Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness.
Plans of Self Care
Plans of Safe Care (POSC) for infants affected by illegal substance abuse have been a requirement in child welfare legislation since 2003, but, with these increases in opioid use disorder and neonatal abstinence syndrome, the focus on planning for the safe care of infants and support for their families has intensified.